Korea Investment Partners is a prominent venture capital and private equity firm based in Seoul, South Korea, with over 30 years of experience in the investment sector. Founded in 1986, the firm focuses on supporting bold and innovative entrepreneurs across various industries, including biotechnology, healthcare, interactive content, media, consumer internet, financial technology, information and communication technology, digitalization, semiconductor, and industrial sectors. Korea Investment Partners has established a strong track record by investing in notable companies such as Kakao, Naver, YG Entertainment, Bodyfriend, and Didi Chuxing. The firm manages more than 20 venture and private equity funds, with total assets under management amounting to approximately $1.8 billion. In addition to its headquarters in Seoul, Korea Investment Partners has offices in Shanghai, Beijing, and Sunnyvale, allowing it to operate on a global scale.
MyHerb Healthcare proivdes a specialized analysis for nutritional supplements.
Brave Company
Series A in 2024
Brave Company is a wellness enterprise that develops and markets consumer health brands, including products like chicken breast and diet convenience foods. Its core mission is to transform global everyday health by integrating its offerings into daily routines, fostering a healthier lifestyle through exercise, nutrition, and social engagement. The company achieves this by supporting and collaborating with creators, providing them with brand incubation, marketing support, personalized recommendations, performance analytics, and offline fitness facilities.
Dr.Diary
Series B in 2022
Dr.Diary is a company that provides a comprehensive diabetes management application aimed at helping users monitor and manage their condition effectively. Founded in 2017 and based in Seoul, South Korea, the application allows users to track their blood glucose levels, exercise routines, and food intake, while offering insights on how these factors influence their health. In addition to these features, the platform includes medicine intake reminders, monthly health reports, and daily tips on diabetes management. It also facilitates communication with friends and provides personal consultation services with healthcare professionals, enhancing the overall user experience in managing diabetes.
Genome
Series B in 2018
Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.
Genome
Series A in 2017
Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.